Previous 10 |
home / stock / nvsef / nvsef news
The 180-day lockup period for Castle Biosciences Inc . ( CSTL ) ends on January 21, 2020 . When the lockup ends, company's pre-IPO shareholders and insiders may choose to sell more than 10.4 million shares of CSTL in the secondary market. The number of currently-restricted shares dwarfs the ...
Source: CNN. Background As the Warren Buffett Indicator keeps flirting with the all-time high (see below), long-term value/quality-focused investors in the U.S. may want to reduce their home-country bias a bit by looking overseas in order to expand the investable universe. Source: G...
Investors in the week ahead will receive an update on Switzerland’s unemployment rate, amid continued strength in its labor market, despite certain companies’ ongoing efforts to slash their workforce. Although some firms, including Austrian bank Raiffeisen and Swiss pharma gian...
Actionable Conclusions (1-10): Brokers Estimated Top 10 High Yield Healthcare "Safer" Dividend Stocks to Net 9% to 22.98% Gains To June 2019 Five of ten top "safer" dividend Healthcare stocks by yield (shaded in the chart above) were verified as being among the top 10 gainers for the comin...
News, Short Squeeze, Breakout and More Instantly...
Novartis Ag Basel Akt Company Name:
NVSEF Stock Symbol:
OTCMKTS Market:
Novartis Ag Basel Akt Website:
FDA approval of the company’s second US Radioligand Therapy (RLT) manufacturing facility increases RLT production capacity to 250,000 doses in 2024 and beyond New 70,000-square foot RLT facility is the company’s largest and most advanced in the world to date and centrall...
APPLY-PNH extension data show that continuous Fabhalta ® (iptacopan) treatment in adults with paroxysmal nocturnal hemoglobinuria (PNH) enabled sustained hemoglobin-level increases to near-normal (≥12 g/dL), blood transfusion avoidance, and improved patient-reported fatigu...
With 5.6 months of additional follow-up and 78.3% of patients having completed Kisqali ® (ribociclib) investigational treatment, the updated analysis shows sustained iDFS benefit and stability in secondary endpoints including overall survival (OS) 1,2 iDFS...